Compare Noble Corporation plc (NE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Travere Therapeutics Inc. Common Stock — how do they compare? Noble Corporation plc trades at $42.9 (market cap $6.93B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Noble Corporation plc is the larger of the two by market cap, and Noble Corporation plc pays a 4.61% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 27 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NE | TVTX | |
|---|---|---|
Market Cap | $6.93B | $4.88B |
Volume | 747,410 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $54.37 | $67.52 |
52-Week Low | $27.45 | $26.79 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $8.36B | $5.01B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $43.42, up 1.12% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income falling to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though investor sentiment is tempered by an ongoing legal investigation and inconsistent quarterly earnings performance.
Outlook remains cautious with analyst consensus price target of $52 offering 20% upside potential, but risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. The stock presents moderate opportunity for value investors given reasonable valuation multiples, but requires careful monitoring of contract execution and resolution of legal matters.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
